

Ali Rohman,^{a,b,c} Niels van
Oosterwijk^a and Bauke W.
Dijkstra^{a*}

^aLaboratory of Biophysical Chemistry,
University of Groningen, Nijenborgh 7,
9747 AG Groningen, The Netherlands,

^bDepartment of Chemistry, Faculty of Sciences
and Technology, Airlangga University, Kampus
C Unair, Jl. Mulyorejo, Surabaya 60115,
Indonesia, and ^cInstitute of Tropical Disease,
Airlangga University, Kampus C Unair,
Jl. Mulyorejo, Surabaya 60115, Indonesia

Correspondence e-mail: b.w.dijkstra@rug.nl

Received 20 February 2012

Accepted 13 March 2012

Purification, crystallization and preliminary X-ray crystallographic analysis of 3-ketosteroid Δ^1 -dehydrogenase from *Rhodococcus erythropolis* SQ1

3-Ketosteroid Δ^1 -dehydrogenase plays a crucial role in the early steps of steroid degradation by introducing a double bond between the C1 and C2 atoms of the A-ring of its 3-ketosteroid substrates. The 3-ketosteroid Δ^1 -dehydrogenase from *Rhodococcus erythropolis* SQ1, a 56 kDa flavoprotein, was crystallized using the sitting-drop vapour-diffusion method at room temperature. The crystals grew in various buffers over a wide pH range (from pH 5.5 to 10.5), but the best crystallization condition consisted of 2%(v/v) PEG 400, 0.1 M HEPES pH 7.5, 2.0 M ammonium sulfate. A native crystal diffracted X-rays to 2.0 Å resolution. It belonged to the primitive orthorhombic space group $P2_12_12_1$, with unit-cell parameters $a = 107.4$, $b = 131.6$, $c = 363.2$ Å, and contained eight molecules in the asymmetric unit. The initial structure of the enzyme was solved using multi-wavelength anomalous dispersion (MAD) data collected from a Pt-derivatized crystal.

1. Introduction

The microbial biotransformation of steroids has attracted substantial interest in the pharmaceutical industry since the 1950s (Fernandes *et al.*, 2003; Mahato & Garai, 1997). Through their biotransformation, a large variety of physiologically active steroid intermediates are produced (Horinouchi *et al.*, 2003; Sedlacek, 1988). These intermediates and their derivatives are utilized extensively as drugs and hormones because of their anti-inflammatory, diuretic, anabolic, contraceptive, anti-androgenic, progestational and anticancer properties (Donova, 2007; Mahato & Garai, 1997). The microbial steroid catabolic pathway has received even more attention since the discovery that this pathway is closely related to the pathogenicity of several pathogenic bacteria, *e.g.* *Mycobacterium tuberculosis* (van der Geize *et al.*, 2007) and *Rhodococcus equi* (van der Geize *et al.*, 2011). In particular, the degradation of cholesterol was shown to be crucial for *M. tuberculosis* to persist in the severe environment of the host macrophages (van der Geize *et al.*, 2007). *M. tuberculosis* is able to use cholesterol as a sole carbon and energy source, converting the C atoms of the steroid nucleus to energy while the aliphatic side-chain atoms are used as a carbon source (Pandey & Sassetti, 2008). For this purpose, *M. tuberculosis* H37Rv contains a large gene cluster coding for enzymes catalyzing cholesterol degradation, including a 3-ketosteroid Δ^1 -dehydrogenase (Rv3537; van der Geize *et al.*, 2007).

3-Ketosteroid Δ^1 -dehydrogenase [4-ene-3-oxosteroid:(acceptor)-1-ene-oxoreductase; EC 1.3.99.4] catalyzes the insertion of a double bond between the C1 and C2 atoms of the chemically stable





Figure 1
An example of the reaction catalyzed by 3-ketosteroid Δ^1 -dehydrogenase.

3-ketosteroid A-ring (Fig. 1). Enzymes with this activity have been discovered in several steroid-degrading bacteria, including bacteria from the genera *Arthrobacter*, *Comamonas*, *Mycobacterium* and *Rhodococcus* (formerly *Nocardia*; Donova, 2007; Horinouchi *et al.*, 2003). Together with the activity of a 3-ketosteroid 9 α -hydroxylase, insertion of this double bond facilitates the opening of the steroid B-ring as a first step in degradation of the steroid nucleus (Horinouchi *et al.*, 2003). The activity of the dehydrogenase is dependent on FAD (flavin adenine dinucleotide) and requires the presence of a carbonyl group at the C3 position of the steroid substrate (Itagaki, Matushita *et al.*, 1990; Itagaki, Wakabayashi *et al.*, 1990). The enzyme acts on a variety of 3-ketosteroid substrates, with a preference for substrates possessing a double bond at the C4–C5 position (Itagaki, Wakabayashi *et al.*, 1990; Knol *et al.*, 2008) such as, for example, the main catabolic steroid intermediate 4-androstene-3,17-dione (Fig. 1).

The catalytic mechanism of 3-ketosteroid Δ^1 -dehydrogenase has been studied for a long time. Levy & Talalay (1959) suggested that the dehydrogenation proceeds directly, excluding the possibility of the formation of a hydroxylated intermediate, and proposed that the enzyme uses a flavin prosthetic group as coenzyme, which was later confirmed to be FAD (Itagaki, Wakabayashi *et al.*, 1990). Ringold *et al.* (1963) showed by isotopic exchange experiments that the dehydrogenase prefers a *trans*-diaxial elimination of the 1 α ,2 β H atoms from a 3-ketosteroid substrate rather than *cis*-elimination, and proposed a two-step mechanism starting with the enolization of the C3 carbonyl keto function in concert with a proton departing from C2 and followed by abstraction of a hydride ion from C1 by the flavin cofactor. Itagaki, Matushita *et al.* (1990) supported the *trans*-diaxial elimination idea, but put forward a slightly different catalytic mechanism by proposing the formation of a carbanion intermediate instead of the enolization of the steroid substrate. By chemical modification, mutagenesis and kinetics experiments, 3-ketosteroid Δ^1 -dehydrogenase from *R. rhodochrous* (formerly *N. corallina*) was shown to have one or two histidine and arginine residues that are essential for catalytic activity, Tyr121 was shown to play an important role in catalysis and both Tyr104 and Tyr116 were found to be important for binding of the steroid substrates (Matsushita & Itagaki, 1992; Fujii *et al.*, 1999). Moreover, mutagenesis studies on 3-ketosteroid Δ^1 -dehydrogenase isoenzyme 2 from *R. erythropolis* SQ1 (Δ^1 -KSTD2) suggested Ser325 and Thr503 as crucial residues for catalysis (van der Geize *et al.*, 2002).

R. erythropolis SQ1 has three 3-ketosteroid Δ^1 -dehydrogenase isoenzymes: Δ^1 -KSTD1 (van der Geize *et al.*, 2001), Δ^1 -KSTD2 (van der Geize *et al.*, 2002) and Δ^1 -KSTD3 (Knol *et al.*, 2008). Δ^1 -KSTD1 has been expressed in *Escherichia coli* strain BL21 (DE3) at higher levels than was possible with the other two isoenzymes and, in contrast to the latter isoenzymes, could be purified relatively easily (Knol *et al.*, 2008). Amino-acid sequence alignment of Δ^1 -KSTD1 with the sequences of structurally characterized enzymes showed that Δ^1 -KSTD1 has the highest homology to 3-ketosteroid Δ^4 -(5 α)-dehydrogenase from *R. jostii* (van Oosterwijk *et al.*, unpublished work) followed by flavocytochrome *c* fumarate reductase from *Shewanella putrefaciens* (PDB entry 1d4c; Leys *et al.*, 1999), with sequence identities of 28 and 24%, respectively. In an effort to identify the nature and positions of the amino-acid residues involved in catalysis and to clarify the catalytic mechanism of 3-ketosteroid Δ^1 -dehydrogenase, we describe here the successful purification, crystallization and preliminary X-ray crystallographic analysis of Δ^1 -KSTD1. The three-dimensional structure of this enzyme will allow manipulation of its catalytic properties and will facilitate the design of inhibitors that could possibly be developed into efficacious drugs to combat pathogenic steroid-degrading bacteria.

2. Experimental

2.1. Expression and purification

Total DNA from *R. erythropolis* SQ1 has been isolated (van der Geize *et al.*, 2000) and characterized to contain three genes, *kstD1* (van der Geize *et al.*, 2001), *kstD2* (van der Geize *et al.*, 2002) and *kstD3* (Knol *et al.*, 2008), that code for three different 3-ketosteroid Δ^1 -dehydrogenases. The *kstD1* gene (1533 bp; GenBank accession No. AF096929) has been cloned into the *NdeI/BamHI* restriction sites of pET15b (Novagen) as pET15b-*kstD1* plasmid and a protocol for the heterologous expression of the Δ^1 -KSTD1 protein in *E. coli* strain BL21 (DE3) has been established (Knol *et al.*, 2008).

An overnight preculture of the recombinant *E. coli* was prepared from a glycerol stock in LB (Luria–Bertani) medium supplemented with 25 $\mu\text{g ml}^{-1}$ carbenicillin (Duchefa Biochemie) by shaking at 200 rev min $^{-1}$ at 310 K. This preculture was used for a 1% inoculation of 1 l fresh LB medium containing 500 mM sorbitol, 2.5 mM betaine, 25 $\mu\text{g ml}^{-1}$ carbenicillin and 100 μM IPTG (isopropyl β -D-1-thiogalactopyranoside; Promega). The *E. coli* cells were grown by shaking at 200 rev min $^{-1}$ at 290 K and harvested after 48 h by centrifugation at 6000g for 15 min.

The cell pellet was resuspended in 30 ml buffer A [50 mM Tris–HCl pH 8.5, 100 mM NaCl, 10% (v/v) glycerol, 5 mM β -mercaptoethanol, 10 mM imidazole]. After supplementation with FAD (25 μmol ; Sigma), complete EDTA-free protease-inhibitor cocktail (one tablet; Roche Diagnostics) and DNase I (catalytic amount; Roche Diagnostics), the cell suspension was lysed by three passages through a French press (Fisher Scientific) at 55 MPa and centrifuged at 35 000g for 15 min to remove cell debris. For immobilized Ni $^{2+}$ -affinity chromatography, cleared supernatant was applied onto a 5 ml HisTrap HP (GE Healthcare) column pre-equilibrated with buffer A and washed with three column volumes of the same buffer. Elution was carried out using a linear imidazole gradient (10–300 mM) in buffer A. The yellow-coloured Δ^1 -KSTD1 fractions were pooled, diluted five times with buffer B [25 mM bicine [N,N-bis(2-hydroxyethyl)glycine] pH 8.5, 10% (v/v) glycerol, 5 mM β -mercaptoethanol] and loaded onto a 6 ml Resource Q (GE Healthcare) anion-exchange column pre-equilibrated with buffer B. After washing the column with 20 and 150 mM NaCl in buffer B (three column volumes each), Δ^1 -KSTD1 was eluted with 250 mM NaCl in the same buffer. Fractions containing Δ^1 -KSTD1 were combined, concentrated to about 100 mg ml $^{-1}$ using an Amicon Ultra-4 30K (Millipore) filter and applied onto a Superdex 200 10/300 GL column (GE Healthcare) pre-equilibrated with buffer C [25 mM bicine pH 9.0, 100 mM NaCl, 10% (v/v) glycerol] for size-exclusion chromatography. Δ^1 -KSTD1 was eluted from the column with the same buffer at a flow rate of 0.5 ml min $^{-1}$. The purified Δ^1 -KSTD1 was finally concentrated to 50 mg ml $^{-1}$ using an Amicon Ultra-4 30K filter and stored at 253 K until use.

All chromatographic experiments were performed using an ÄKTAexplorer (GE Healthcare). Protein concentrations were determined using the Bradford protein assay kit (Bio-Rad) with BSA (bovine serum albumin) as a standard and protein purity was monitored by Coomassie Blue-stained SDS–PAGE.

2.2. ThermoFAD stability assay

To find a buffer system in which Δ^1 -KSTD1 is stable, a ThermoFAD (Thermofluor-adapted flavin *ad hoc* detection system) assay was carried out according to Forneris *et al.* (2009) using a buffer screen of MMT buffer {1:2:2 DL-malic acid:MES [2-(N-morpholino)ethanesulfonic acid]:Tris} ranging from pH 4.0 to 9.0. Samples of 25 μl had a

Table 1

Summary of crystallographic data collection and processing.

Values in parentheses are for the highest resolution shell.


Data set	Native	Pt derivative		
		Peak	Inflection	Remote
Beamline	ID14-1, ESRF	PXI, SLS		
Detector	ADSC Q210	PILATUS		
Wavelength (Å)	0.93340	1.07240	1.07270	1.06320
Resolution (Å)	2.00 (2.11–2.00)	3.30 (3.48–3.30)	3.50 (3.69–3.50)	3.70 (3.90–3.70)
Space group	$P2_12_12_1$	$P2_12_12_1$	$P2_12_12_1$	$P2_12_12_1$
Unit-cell parameters				
a (Å)	107.4	109.5	110.1	110.4
b (Å)	131.6	129.8	130.3	130.6
c (Å)	363.2	361.5	362.6	363.3
$\alpha = \beta = \gamma$ (°)	90	90	90	90
Molecules per asymmetric unit	8	8	8	8
Matthews coefficient (Å ³ Da ⁻¹)	2.9	2.9	2.9	2.9
Solvent content (%)	57	57	58	58
$R_{\text{merge}}^{\dagger}$	0.084 (0.752)	0.142 (0.783)	0.156 (0.902)	0.184 (0.957)
$R_{\text{p.i.m.}}^{\ddagger}$	0.050 (0.450)	0.040 (0.216)	0.044 (0.260)	0.052 (0.267)
Total observations	1296759 (183757)	1057045 (156992)	883593 (118606)	762547 (111309)
Unique reflections	345382 (49404)	78506 (11309)	66511 (9323)	57113 (8220)
Mean $I/\sigma(I)$	10.9 (1.8)	15.1 (3.8)	15.0 (3.3)	13.1 (3.4)
Completeness (%)	99.8 (98.6)	100.0 (100.0)	99.5 (96.9)	100.0 (100.0)
Multiplicity	3.8 (3.7)	13.5 (13.9)	13.3 (12.7)	13.4 (13.5)

$\dagger R_{\text{merge}} = \sum_{hkl} \sum_i |I_i(hkl) - \langle I(hkl) \rangle| / \sum_{hkl} \sum_i I_i(hkl)$. $\ddagger R_{\text{p.i.m.}} = \sum_{hkl} \{1/[N(hkl) - 1]\}^{1/2} \sum_i |I_i(hkl) - \langle I(hkl) \rangle| / \sum_{hkl} \sum_i I_i(hkl)$, where $I_i(hkl)$ is the integrated intensity of a reflection, $\langle I(hkl) \rangle$ is the mean intensity of multiple corresponding symmetry-related reflections and N is the multiplicity of the given reflections.

typical composition (final concentration) of 100 mM MMT, 100 mM NaCl, 10% (v/v) glycerol and 2.5 mg ml⁻¹ protein. The samples were analyzed in a 96-well thin-wall PCR plate (Bio-Rad) sealed with optical quality sealing tape (Bio-Rad). The sealed plate was inserted into a real-time PCR machine (iCycler, Bio-Rad) and was heated from 293 to 363 K with a 0.5 K increment per 20 s. The changes in the fluorescence of FAD were recorded every 0.5 K after a 10 s hold using a fluorescence detector (MyIQ single-colour RT-PCR detection system, Bio-Rad) with an excitation-wavelength range between 470 and 500 nm and a SYBR Green fluorescence emission filter (523–543 nm).

2.3. Crystallization

Prior to crystallization experiments, the protein sample was thawed on ice and its concentration was adjusted to 15 mg ml⁻¹ with buffer C. Crystallization conditions were screened using the JCSG-plus Screen (Molecular Dimensions Ltd), Structure Screens I and II (Molecular Dimensions Ltd) and Wizard Screens I and II (Emerald BioSystems).

**Figure 2**

Thermostability analysis of Δ^1 -KSTD1 in MMT buffer at various pH values using the ThermoFAD method (Forneris *et al.*, 2009). The melting temperature (T_m), which is defined as the midpoint temperature of the protein folding–unfolding transition (Ericsson *et al.*, 2006), is determined as the temperature at which the first derivative d(flourescence)/dT is maximal.

Crystallization experiments were performed by the sitting-drop vapour-diffusion method using MRC 2-Well Crystallization Plates (Swissci). These experiments were performed with a Mosquito (TTP LabTech) crystallization robot by mixing 0.15 μ l screen solution with 0.15 μ l protein solution. After equilibration against 50 μ l screen solution for 5–7 d, bright yellow rectangular crystals were observed in several conditions. For X-ray data collection, Δ^1 -KSTD1 crystals were routinely reproduced using condition No. 30 of Structure Screen I [2% (v/v) PEG (polyethylene glycol) 400, 0.1 M HEPES (*N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid) buffer pH 7.5, 2.0 M ammonium sulfate] as the crystallization solution. All crystallization experiments were carried out at 293 K.

2.4. Data collection and processing

For X-ray diffraction experiments, the crystals were cryoprotected by transferring them for 5 s into crystallization solution containing 40% (w/v) sucrose, followed by a 1 s transfer into a 1:1 mixture of paraffin oil and Paratone-N, before flash-cooling them in liquid nitrogen. A Pt derivative was prepared by washing a crystal with 2% (v/v) PEG 400, 0.1 M HEPES pH 7.5, 0.4 M NaH₂PO₄/1.6 M K₂HPO₄, followed by soaking the crystal overnight in the same solution but containing 10 mM Na₂PtCl₄. The Pt-derivatized crystal was cryoprotected in a similar way to the native crystals.

X-ray diffraction data sets were collected at 100 K on beamline ID14-1 (European Synchrotron Radiation Facility, Grenoble) using an ADSC Quantum Q210 detector (native crystal) or on beamline PXI (Swiss Light Source, Villigen) using a PILATUS detector (Pt-derivatized crystal). The native crystal data set was recorded at a wavelength of 0.93340 Å for 450 frames with an oscillation range per frame of 0.2°. Based on an XAFS (X-ray absorption fine-structure) measurement, MAD data collection was carried out from a single Pt-derivatized crystal at three wavelengths corresponding to peak (1.07240 Å), inflection point (1.07270 Å) and remote (1.06320 Å). At each wavelength, a 720-frame data set was collected to a maximum resolution of 3.1 Å with an oscillation range per frame of 0.5°.

All data sets were processed and integrated using the program XDS (Kabsch, 2010) in combination with the program SCALA

(Evans, 2006) from the *CCP4* package (Winn *et al.*, 2011). Table 1 presents pertinent crystallographic details on data collection and processing. Initial phases were calculated by submitting the MAD data to *autoSHARP* (Vonnrhein *et al.*, 2007). Because of non-isomorphism between the native and Pt-derivatized crystals, phases for the native diffraction data were obtained with the program *Phaser* (McCoy *et al.*, 2007) by placing the structure of 3-ketosteroid Δ^4 -(5 α)-dehydrogenase from *R. jostii* (van Oosterwijk *et al.*, unpublished work) in the electron-density map obtained from *autoSHARP*. The resulting phases were used for automatic building using the program *ARP/wARP* (Langer *et al.*, 2008).

3. Results and discussion

Δ^1 -KSTD1 is a flavoprotein that contains 510 amino-acid residues. However, the recombinant protein expressed in *E. coli* from the pET15b-kstD1 plasmid also contains a 20-amino-acid leader sequence (MGSSHHHHHHSSGLvprgsH) which includes a 6 \times His tag (bold)

and a thrombin cleavage site (lower case). Thus, the expressed protein contains 530 amino-acid residues with a calculated molecular mass of 55 995 Da (including one FAD molecule) and a theoretical pI (isoelectric point) of 4.73 (as calculated using <http://web.expasy.org/protparam/>).

Because of its relatively low pI, Δ^1 -KSTD1 was initially purified in a sodium phosphate buffer system at pH 7.2 and was stored prior to crystallization in 25 mM sodium phosphate buffer pH 7.2, 100 mM NaCl, 10% (v/v) glycerol. Fresh protein obtained in this way could be crystallized using Structure Screen II condition No. 29 (0.2 M potassium/sodium tartrate, 0.1 M citrate pH 5.6, 2 M ammonium sulfate). However, despite intensive efforts to optimize the crystallization conditions and procedure (e.g. by varying the concentrations of the various crystallization solution components, the pH and the crystallization method, as well as by applying various seeding techniques), the crystals grew slowly (in about three months) and the reproducibility was very low. Therefore, we considered that storage could negatively affect the quality and crystallizability of Δ^1 -KSTD1. Because Δ^1 -KSTD1 is a flavoprotein, a *ThermoFAD* (Forneris *et al.*,




Figure 3

Δ^1 -KSTD1 crystals obtained from various crystallization screens. (a) JCSG-plus condition No. 50 (0.2 M NaCl, 0.1 M sodium cacodylate pH 6.5, 2 M ammonium sulfate). (b) JCSG-plus condition No. 83 (0.1 M bis-Tris pH 5.5, 2 M ammonium sulfate). (c) Structure Screen I condition No. 30 [2% (v/v) PEG 400, 0.1 M HEPES pH 7.5, 2 M ammonium sulfate]. (d) Structure Screen I condition No. 32 (0.1 M Tris-HCl pH 8.5, 2 M ammonium sulfate). (e) Structure Screen I condition No. 44 (2 M ammonium sulfate). (f) Structure Screen II condition No. 23 [10% (v/v) dioxane, 0.1 M MES pH 6.5, 1.6 M ammonium sulfate]. (g) Structure Screen II condition No. 29 (0.2 M potassium/sodium tartrate, 0.1 M citrate pH 5.6, 2 M ammonium sulfate). (h) Wizard Screen I condition No. 20 (0.2 M NaCl, 0.1 M imidazole pH 8.0, 0.4 M NaH₂PO₄/1.6 M K₂HPO₄). (i) Wizard Screen I condition No. 33 [0.2 M Li₂SO₄, 0.1 M CAPS (*N*-cyclohexyl-3-aminopropanesulfonic acid) pH 10.5, 2 M ammonium sulfate].

2009) assay was carried out to find a buffer system in which the protein was more stable. By thermally denaturing a protein and exposing (or dissociating) its buried FAD to the solvent, the assay reports on the thermal stability of a flavoprotein by way of its apparent melting temperature (T_m). Although there is no quantitative correlation between protein stability and crystallizability, for a particular protein a buffer system in which the protein is more stable gives a higher probability of the protein crystallizing (Ericsson *et al.*, 2006). Below pH 6.0 no apparent T_m is observed, indicating that Δ^1 -KSTD1 is destabilized at low pH. In the pH 6.0–9.0 range we observed that the higher the pH value, the higher the apparent T_m of Δ^1 -KSTD1 (Fig. 2). At pH 9.0 the apparent T_m of Δ^1 -KSTD1 is about 7 K higher than at pH 7.0. Based on this result, Δ^1 -KSTD1 was purified at pH 8.5 and stored for crystallization at pH 9.0 (buffer C; see §2.1).

Δ^1 -KSTD1 in buffer C could indeed be crystallized more quickly and the crystallization could be reproduced more easily than with protein stored in the initial storage buffer. Crystallization trials using protein purified and stored in this new buffer produced Δ^1 -KSTD1 crystals in 5–7 d in several crystallization conditions (Fig. 3). Except for one condition that contained 0.4 M NaH_2PO_4 /1.6 M K_2HPO_4 , all crystallization conditions contained 1.6 or 2.0 M ammonium sulfate as precipitant. The crystals grew in various buffers in a broad pH range (from pH 5.5 to 10.5) either with or without salts/additives (*e.g.* NaCl, potassium/sodium tartrate, Li_2SO_4 , PEG 400 or dioxane). However, of all of the crystallization conditions, the most reproducible for crystallizing Δ^1 -KSTD1 appeared to be Structure Screen I solution No. 30, which consists of 2% (v/v) PEG 400, 0.1 M HEPES pH 7.5, 2 M ammonium sulfate.

Typically, Δ^1 -KSTD1 crystals grew in rectangular shapes with maximum dimensions of approximately $100 \times 100 \times 300 \mu\text{m}$ and, as they contain FAD, were coloured bright yellow. A complete data set was collected from a native crystal (Fig. 4) and processed to 2.0 Å

resolution (Table 1). The data could be indexed in the primitive orthorhombic space group $P2_12_12_1$, with unit-cell parameters $a = 107.4$, $b = 131.6$, $c = 363.2 \text{ Å}$. With this large unit cell, the crystal contained eight copies of the 56 kDa Δ^1 -KSTD1 molecule (including its 20-amino-acid leader sequence and one FAD molecule) per asymmetric unit, corresponding to a Matthews coefficient (V_M) of $2.9 \text{ Å}^3 \text{ Da}^{-1}$ and a crystal solvent content of 57%.

A structural homology search using the *Fold & Function Assignment* (FFAS) server (Jaroszewski *et al.*, 2005) with the Δ^1 -KSTD1 sequence as a query resulted in the flavocytochrome *c* fumarate reductase from *S. putrefaciens* (PDB entry 1d4c; Leys *et al.*, 1999) as the top hit, with a primary-structure identity of 24% to Δ^1 -KSTD1. However, several attempts to solve the Δ^1 -KSTD1 structure by molecular replacement using the crystal structure of this protein as a starting model were not successful, most likely because its structural similarity to Δ^1 -KSTD1 is too low and/or because there are too many molecules in the asymmetric unit of the Δ^1 -KSTD1 crystal. Moreover, molecular replacement also failed when the structure of the 3-ketosteroid Δ^4 -(5 α)-dehydrogenase from *R. jostii* (van Oosterwijk *et al.*, unpublished work), which shares 28% sequence identity with Δ^1 -KSTD1, was used as input. Therefore, to solve the phase problem, a MAD experiment was conducted using a Δ^1 -KSTD1 crystal soaked in a solution containing Na_2PtCl_4 . Since the crystal initially grew from a solution containing ammonium sulfate, which may compete with the protein to bind the platinum ions (Drenth, 2007), the ammonium sulfate was removed from the crystal by washing and soaking the crystal in 0.4 M NaH_2PO_4 /1.6 M K_2HPO_4 . This latter condition was inspired by another successful crystallization condition for Δ^1 -KSTD1 (Fig. 3h).

A three-wavelength MAD data set was collected from a single Pt-derivatized crystal (Table 1). The data could be processed to resolutions of 3.3, 3.5 and 3.7 Å for the peak, inflection-point and remote wavelengths, respectively, with basically the same unit-cell parameters as for the native crystal. The MAD data sets were collected sequentially at the peak, inflection-point and remote wavelengths; thus, the decreasing resolution is likely to be the result of radiation damage. All data sets were then limited to 3.7 Å resolution and used for phase calculation and density modification with *autoSHARP* (Vonnrhein *et al.*, 2007), which produced an electron-density map suitable for model building (Fig. 5). This map could be used for the manual placement of eight copies of a model of the F-domain of the 3-ketosteroid Δ^4 -(5 α)-dehydrogenase structure (van Oosterwijk *et al.*, unpublished work) and eight copies of its S-domain.




Figure 4
X-ray diffraction image obtained from a Δ^1 -KSTD1 crystal. (a) Diffraction pattern from a native crystal obtained on beamline ID14-1 at the ESRF. The resolution at the edge is 1.8 Å. (b) A close-up view of an area in the frame where the spots are close together, showing the long cell axis.




Figure 5
Electron-density map for Δ^1 -KSTD1 as obtained using *autoSHARP* (Vonnrhein *et al.*, 2007), showing a clear α -helix (arrow).

After several cycles of manual model building, the resulting model was used to solve the native structure of Δ^1 -KSTD1 using *Phaser* (McCoy *et al.*, 2007). Finally, automatic building using the program *ARP/wARP* (Langer *et al.*, 2008) was performed to obtain the complete model for Δ^1 -KSTD1. Refinement and structure analysis are currently under way to unveil the structural basis of the substrate specificity and catalytic mechanism of Δ^1 -KSTD1.

We thank Professor Lubbert Dijkhuizen, Dr Robert van der Geize and Dr Jan Knol of the Department of Microbiology, University of Groningen for providing the pET15b-kstD1 plasmid and initial Δ^1 -KSTD1 protein samples and for helpful discussions. We thank the beamline scientists at ID14-1 (ESRF) and PXI (SLS) for their assistance. AR was the recipient of a scholarship from the Directorate General of Higher Education (DIKTI), the Ministry of Education and Culture, Republic of Indonesia.

References

- Donova, M. V. (2007). *Appl. Biochem. Microbiol.* **43**, 1–14.
- Drenth, J. (2007). *Principles of Protein X-ray Crystallography*, 3rd ed. New York: Springer.
- Ericsson, U. B., Hallberg, B. M., DeTitta, G. T., Dekker, N. & Nordlund, P. (2006). *Anal. Biochem.* **357**, 289–298.
- Evans, P. (2006). *Acta Cryst.* **D62**, 72–82.
- Fernandes, P., Cruz, A., Angelova, B., Pinheiro, H. M. & Cabral, J. M. S. (2003). *Enzyme Microb. Technol.* **32**, 688–705.
- Forneris, F., Orru, R., Bonivento, D., Chiarelli, L. R. & Mattevi, A. (2009). *FEBS J.* **276**, 2833–2840.
- Fujii, C., Morii, S., Kadode, M., Sawamoto, S., Iwami, M. & Itagaki, E. (1999). *J. Biochem.* **126**, 662–667.
- Geize, R. van der, Grommen, A. W., Hessels, G. I., Jacobs, A. A. & Dijkhuizen, L. (2011). *PLoS Pathog.* **7**, e1002181.
- Geize, R. van der, Hessels, G. I. & Dijkhuizen, L. (2002). *Microbiology*, **148**, 3285–3292.
- Geize, R. van der, Hessels, G. I., van Gerwen, R., van der Meijden, P. & Dijkhuizen, L. (2001). *FEMS Microbiol. Lett.* **205**, 197–202.
- Geize, R. van der, Hessels, G. I., van Gerwen, R., Vrijbloed, J. W., van der Meijden, P. & Dijkhuizen, L. (2000). *Appl. Environ. Microbiol.* **66**, 2029–2036.
- Geize, R. van der, Yam, K., Heuser, T., Wilbrink, M. H., Hara, H., Anderton, M. C., Sim, E., Dijkhuizen, L., Davies, J. E., Mohn, W. W. & Eltis, L. D. (2007). *Proc. Natl Acad. Sci. USA*, **104**, 1947–1952.
- Horinouchi, M., Hayashi, T., Yamamoto, T. & Kudo, T. (2003). *Appl. Environ. Microbiol.* **69**, 4421–4430.
- Itagaki, E., Matsushita, H. & Hatta, T. (1990). *J. Biochem.* **108**, 122–127.
- Itagaki, E., Wakabayashi, T. & Hatta, T. (1990). *Biochim. Biophys. Acta*, **1038**, 60–67.
- Jaroszewski, L., Rychlewski, L., Li, Z., Li, W. & Godzik, A. (2005). *Nucleic Acids Res.* **33**, W284–W288.
- Kabsch, W. (2010). *Acta Cryst.* **D66**, 125–132.
- Knol, J., Bodewits, K., Hessels, G. I., Dijkhuizen, L. & van der Geize, R. (2008). *Biochem. J.* **410**, 339–346.
- Langer, G., Cohen, S. X., Lamzin, V. S. & Perrakis, A. (2008). *Nature Protoc.* **3**, 1171–1179.
- Levy, H. R. & Talalay, P. (1959). *J. Biol. Chem.* **234**, 2014–2021.
- Leys, D., Tsupin, A. S., Neelson, K. H., Meyer, T. E., Cusanovich, M. A. & Van Beeumen, J. J. (1999). *Nature Struct. Biol.* **6**, 1113–1117.
- Mahato, S. B. & Garai, S. (1997). *Steroids*, **62**, 332–345.
- Matsushita, H. & Itagaki, E. (1992). *J. Biochem.* **111**, 594–599.
- McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C. & Read, R. J. (2007). *J. Appl. Cryst.* **40**, 658–674.
- Pandey, A. K. & Sassetti, C. M. (2008). *Proc. Natl Acad. Sci. USA*, **105**, 4376–4380.
- Ringold, H. J., Hayano, M. & Stefanovic, V. (1963). *J. Biol. Chem.* **238**, 1960–1965.
- Sedlacek, L. (1988). *Crit. Rev. Biotechnol.* **7**, 187–236.
- Vonrhein, C., Blanc, E., Roversi, P. & Bricogne, G. (2007). *Methods Mol. Biol.* **364**, 215–230.
- Winn, M. D. *et al.* (2011). *Acta Cryst.* **D67**, 235–242.